ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Fundamental Analysis

NASDAQ:ARQT • US03969K1088

26.71 USD
+0.12 (+0.45%)
At close: Feb 12, 2026
26.71 USD
0 (0%)
After Hours: 2/12/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, ARQT scores 3 out of 10 in our fundamental rating. ARQT was compared to 523 industry peers in the Biotechnology industry. ARQT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ARQT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year ARQT has reported negative net income.
  • In the past year ARQT has reported a negative cash flow from operations.
  • In the past 5 years ARQT always reported negative net income.
  • In the past 5 years ARQT always reported negative operating cash flow.
ARQT Yearly Net Income VS EBIT VS OCF VS FCFARQT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -11.95%, ARQT belongs to the top of the industry, outperforming 82.79% of the companies in the same industry.
  • With a decent Return On Equity value of -28.04%, ARQT is doing good in the industry, outperforming 78.01% of the companies in the same industry.
Industry RankSector Rank
ROA -11.95%
ROE -28.04%
ROIC N/A
ROA(3y)-62.08%
ROA(5y)-56.46%
ROE(3y)-177.71%
ROE(5y)-130.52%
ROIC(3y)N/A
ROIC(5y)N/A
ARQT Yearly ROA, ROE, ROICARQT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • The Gross Margin of ARQT (89.96%) is better than 92.54% of its industry peers.
  • ARQT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARQT Yearly Profit, Operating, Gross MarginsARQT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • ARQT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ARQT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ARQT has more shares outstanding
  • ARQT has a better debt/assets ratio than last year.
ARQT Yearly Shares OutstandingARQT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ARQT Yearly Total Debt VS Total AssetsARQT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 6.14 indicates that ARQT is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.14, ARQT is in the better half of the industry, outperforming 75.14% of the companies in the same industry.
  • ARQT has a Debt/Equity ratio of 0.68. This is a neutral value indicating ARQT is somewhat dependend on debt financing.
  • The Debt to Equity ratio of ARQT (0.68) is worse than 71.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Altman-Z 6.14
ROIC/WACCN/A
WACC12.64%
ARQT Yearly LT Debt VS Equity VS FCFARQT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

  • ARQT has a Current Ratio of 3.50. This indicates that ARQT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.50, ARQT is in line with its industry, outperforming 41.87% of the companies in the same industry.
  • A Quick Ratio of 3.28 indicates that ARQT has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.28, ARQT is in line with its industry, outperforming 41.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.5
Quick Ratio 3.28
ARQT Yearly Current Assets VS Current LiabilitesARQT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 79.89% over the past year.
  • The Revenue has grown by 129.21% in the past year. This is a very strong growth!
EPS 1Y (TTM)79.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.18%
Revenue 1Y (TTM)129.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%121.69%

3.2 Future

  • The Earnings Per Share is expected to grow by 36.18% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 37.43% on average over the next years. This is a very strong growth
EPS Next Y84.76%
EPS Next 2Y52.61%
EPS Next 3Y45.49%
EPS Next 5Y36.18%
Revenue Next Year93.65%
Revenue Next 2Y58.84%
Revenue Next 3Y48.8%
Revenue Next 5Y37.43%

3.3 Evolution

ARQT Yearly Revenue VS EstimatesARQT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ARQT Yearly EPS VS EstimatesARQT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ARQT. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 70.02, ARQT can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ARQT indicates a rather cheap valuation: ARQT is cheaper than 88.72% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.69. ARQT is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 70.02
ARQT Price Earnings VS Forward Price EarningsARQT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARQT Per share dataARQT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

  • ARQT's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as ARQT's earnings are expected to grow with 45.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.61%
EPS Next 3Y45.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ARQT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ARCUTIS BIOTHERAPEUTICS INC

NASDAQ:ARQT (2/12/2026, 8:00:00 PM)

After market: 26.71 0 (0%)

26.71

+0.12 (+0.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28
Earnings (Next)02-25
Inst Owners100.16%
Inst Owner Change-5.53%
Ins Owners0.77%
Ins Owner Change-2.53%
Market Cap3.27B
Revenue(TTM)317.93M
Net Income(TTM)-44.32M
Analysts82.86
Price Target32.39 (21.27%)
Short Float %13.78%
Short Ratio8.29
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)89.16%
Min EPS beat(2)19.41%
Max EPS beat(2)158.91%
EPS beat(4)4
Avg EPS beat(4)62.58%
Min EPS beat(4)6.63%
Max EPS beat(4)158.91%
EPS beat(8)8
Avg EPS beat(8)44.88%
EPS beat(12)12
Avg EPS beat(12)33.61%
EPS beat(16)15
Avg EPS beat(16)26.67%
Revenue beat(2)2
Avg Revenue beat(2)10.14%
Min Revenue beat(2)8.44%
Max Revenue beat(2)11.84%
Revenue beat(4)4
Avg Revenue beat(4)10.07%
Min Revenue beat(4)3.7%
Max Revenue beat(4)16.29%
Revenue beat(8)8
Avg Revenue beat(8)38.61%
Revenue beat(12)11
Avg Revenue beat(12)29.33%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.4%
PT rev (3m)35.83%
EPS NQ rev (1m)52.09%
EPS NQ rev (3m)71.86%
EPS NY rev (1m)13.52%
EPS NY rev (3m)15.33%
Revenue NQ rev (1m)1.34%
Revenue NQ rev (3m)1.8%
Revenue NY rev (1m)0.47%
Revenue NY rev (3m)0.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 70.02
P/S 10.29
P/FCF N/A
P/OCF N/A
P/B 20.7
P/tB 22.93
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)0.38
Fwd EY1.43%
FCF(TTM)-0.39
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS2.6
BVpS1.29
TBVpS1.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.95%
ROE -28.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.96%
FCFM N/A
ROA(3y)-62.08%
ROA(5y)-56.46%
ROE(3y)-177.71%
ROE(5y)-130.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 0.68
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 343.84%
Cap/Sales 4.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.5
Quick Ratio 3.28
Altman-Z 6.14
F-Score5
WACC12.64%
ROIC/WACCN/A
Cap/Depr(3y)909.75%
Cap/Depr(5y)643.63%
Cap/Sales(3y)211.41%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.18%
EPS Next Y84.76%
EPS Next 2Y52.61%
EPS Next 3Y45.49%
EPS Next 5Y36.18%
Revenue 1Y (TTM)129.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%121.69%
Revenue Next Year93.65%
Revenue Next 2Y58.84%
Revenue Next 3Y48.8%
Revenue Next 5Y37.43%
EBIT growth 1Y78.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year98.71%
EBIT Next 3Y46.98%
EBIT Next 5Y32.75%
FCF growth 1Y81.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.57%
OCF growth 3YN/A
OCF growth 5YN/A

ARCUTIS BIOTHERAPEUTICS INC / ARQT FAQ

What is the ChartMill fundamental rating of ARCUTIS BIOTHERAPEUTICS INC (ARQT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ARQT.


What is the valuation status for ARQT stock?

ChartMill assigns a valuation rating of 2 / 10 to ARCUTIS BIOTHERAPEUTICS INC (ARQT). This can be considered as Overvalued.


What is the profitability of ARQT stock?

ARCUTIS BIOTHERAPEUTICS INC (ARQT) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for ARQT stock?

The Earnings per Share (EPS) of ARCUTIS BIOTHERAPEUTICS INC (ARQT) is expected to grow by 84.76% in the next year.